Browse medicines

Use listed on the medicine record

Moderate to severe plaque psoriasis

Use listed on the medicine record

The following autoinflammatory Periodic Fever Syndromes

Use listed on the medicine record

Adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma (MCC) [see Clinical Studies (14

Use listed on the medicine record

Postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors fo

Use listed on the medicine record

High-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy

Use listed on the medicine record

Resectable (tumors ≥ 4 cm and/or node positive) non-small cell lung cancer (NSCLC) and no known epidermal growth factor

Use listed on the medicine record

Allergic reactions (Type I), including anaphylaxis, that may occur with accidental exposure to one or more foods

Use listed on the medicine record

Severe asthma aged 18 years and older with an eosinophilic phenotype

Use listed on the medicine record

Multicentric Castleman's disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative

Use listed on the medicine record

Metastatic NSCLC who have disease progression during or following platinum-containing chemotherapy

Use listed on the medicine record

Acute organ rejection

Use listed on the medicine record

Eosinophilic granulomatosis with polyangiitis

Use listed on the medicine record

Moderately to severely active rheumatoid arthritis

Use listed on the medicine record

TREMFYA is an interleukin-23 antagonist indicated for the treatment of: adults and pediatric patients 6 years of age and older who also weigh at least 40 kg with moderate-to-severe plaque psoriasis and who are candidates for systemic therapy or phototherapy. ( 1.1 ) adults and pediatric patients 6 years of age and older who also weigh at least 40 kg with active psoriatic arthritis. ( 1.2 ) adults with moderately to severely active ulcerative colitis. ( 1.3 ) adults with moderately to severely active Crohn's disease.

Use listed on the medicine record

Patients 6 years of age and older with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy

Use listed on the medicine record

Severe asthma with an eosinophilic phenotype

Use listed on the medicine record

OCREVUS is indicated for the treatment of: Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults Primary progressive MS, in adults Relapsing-remitting MS, in pediatric patients 10 years of age and older who weigh 25 kg or more.

Use listed on the medicine record

KEVZARA ® is an interleukin-6 (IL-6) receptor antagonist indicated for treatment of: adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to one or more disease-modifying antirheumatic drugs (DMARDs). ( 1.1 ) adult patients with polymyalgia rheumatica (PMR) who have had an inadequate response to corticosteroids or who cannot tolerate corticosteroid taper. ( 1.2 ) patients who weigh 63 kg or greater with active polyarticular juvenile idiopathic arthritis (pJIA).

Use listed on the medicine record

TOFIDENCE ® (tocilizumab-bavi) is an interleukin-6 (IL-6) receptor antagonist indicated for treatment of: Rheumatoid Arthritis (RA) ( 1.1 ) Adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs). Giant Cell Arteritis (GCA) ( 1.2 ) Adult patients with giant cell arteritis. Polyarticular Juvenile Idiopathic Arthritis (PJIA) ( 1.3 ) Patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis.

Use listed on the medicine record

Moderate-to-severe atopic dermatitis

Use listed on the medicine record

REMICADE is a tumor necrosis factor (TNF) blocker indicated for: Crohn's Disease : reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy. ( 1.1 ) reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing disease.

Use listed on the medicine record

ENTYVIO is indicated in adults for the treatment of: moderately to severely active ulcerative colitis (UC). moderately to severely active Crohn's disease (CD). ENTYVIO is an integrin receptor antagonist indicated in adults for the treatment of: moderately to severely active ulcerative colitis (UC). ( 1 ) moderately to severely active Crohn's disease (CD). ( 1 )

Use listed on the medicine record

Relapsing forms of multiple sclerosis (MS), to include relapsing-remitting disease and active secondary progressive disease

Use listed on the medicine record

Metastatic colorectal cancer (CRC) with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy

Use listed on the medicine record

The treatment of adult patients with multiple myeloma

Use listed on the medicine record

Infection caused by Orthoebolavirus zairense

Use listed on the medicine record

Patients 5 years of age and older

Use listed on the medicine record

Recurrence of Clostridioides difficile infection

Use listed on the medicine record

Adult and pediatric patients one month and older

Use listed on the medicine record

• EMPLICITI is indicated in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received one to three prior therapies. • EMPLICITI is indicated in combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.

Use listed on the medicine record

ELREXFIO is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. This indication is approved under accelerated approval based on response rate and durability of response [see Clinical Studies (14) ] . Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s).

Use listed on the medicine record

Serious lower respiratory tract disease caused by respiratory syncytial virus

Use listed on the medicine record

Inhalational anthrax due to Bacillus anthracis

Use listed on the medicine record

Neuromyelitis optica spectrum disorder

Use listed on the medicine record

Routine prophylaxis to prevent or reduce the frequency of bleeding episodes

Use listed on the medicine record

SOLIRIS is a complement inhibitor indicated for: the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis. ( 1.1 ) the treatment of patients with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy. ( 1.2 ) Limitation of Use SOLIRIS is not indicated for the treatment of patients with Shiga toxin E. coli related hemolytic uremic syndrome (STEC-HUS).

Use listed on the medicine record

Previously untreated chronic lymphocytic leukemia

Use listed on the medicine record

Infection caused by Orthoebolavirus zairense

Use listed on the medicine record

KESIMPTA is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. KESIMPTA is a CD20-directed cytolytic antibody indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. ( 1 )

Use listed on the medicine record

HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease [see

Use listed on the medicine record

YERVOY is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody indicated for: Melanoma • Treatment of unresectable or metastatic melanoma in adults and pediatric patients 12 years and older as a single agent or in combination with nivolumab. (1.1) • Adjuvant treatment of adult patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm who have undergone complete resection, including total lymphadenectomy.

Use listed on the medicine record

KRAS G12C- mutated mCRC, as determined by an FDA-approved test, who have received prior treatment with fluoropyrimidine-

Use listed on the medicine record

Infection caused by Orthoebolavirus zairense

Use listed on the medicine record

Inhalational anthrax due to Bacillus anthracis

Use listed on the medicine record

Metastatic colorectal cancer with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrim